Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience. (May 2016)

• Record Type: Journal Article
• Authors: Meattini, Icro; Desideri, Isacco; Di Cataldo, Vanessa; Francolini, Giulio; De Luca Cardillo, Carla; Scotti, Vieri; Loi, Mauro; Detti, Beatrice; Mangoni, Monica; Agresti, Benedetta; Baldazzi, Valentina; Greto, Daniela; Casella, Donato; Bernini, Marco; Sanchez, Luis Jose; Orzalesi, Lorenzo; Nori, Jacopo; Fambrini, Massimiliano; Bianchi, Simonetta; Livi, Lorenzo
• Is Part Of: Future oncology. Volume 12:Number 9(2016)
• Page Start: 1117
• Page End: 1124
• Publication Date: 2016-05
• Subjects: concomitant radiotherapy -- eribulin mesylate -- metastatic breast cancer -- safety -- toxicity; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2015-0059
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: This study evaluates, for the first time, the safety of eribulin in metastatic breast cancer patients concomitantly treated with palliative radiotherapy (RT).Patients & materials: A total of 17 patients were pretreated for metastatic breast cancer. Patients received eribulin mesylate and bone RT.Results: The most frequent grade 3 hematologic adverse events were neutropenia (56%) and anemia (20%). Mean pain score decreased from 2 (baseline) to 0.7 (end of observation). Analgesic score remained stable (1.8 vs 1.6). Bone pain scores dropped within a few weeks and remained below baseline values throughout the analysis. The overall response rate was 29%, and the clinical benefit rate was 59%.Conclusion: Eribulin is characterized by a manageable safety profile also when combined with palliative RT.